JMP Securities Keeps a Buy Rating on DBV Technologies SA – American (DBVT)


JMP Securities analyst Liisa Bayko reiterated a Buy rating on DBV Technologies SA – American (DBVT) today and set a price target of $20. The company’s shares opened today at $8.75.

According to TipRanks.com, Bayko is a 5-star analyst with an average return of 17.0% and a 50.9% success rate. Bayko covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Sarepta Therapeutics, and Aimmune Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for DBV Technologies SA – American with a $12.86 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.77 and a one-year low of $3.60. Currently, DBV Technologies SA – American has an average volume of 847.3K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

DBV Technologies SA is a clinical-stage biopharmaceutical company, which deals with conducting of research and development of epicutaneous immunotherapy products. It focuses on developing a novel technology platform called Viaskin, which is an electrostatic patch that offers a convenient, self-administered, non-invasive immunotherapy to patients.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts